DK3099709T3 - Midler og fremgangsmåder til fremstilling af stabile antistoffer - Google Patents
Midler og fremgangsmåder til fremstilling af stabile antistoffer Download PDFInfo
- Publication number
- DK3099709T3 DK3099709T3 DK15704857.0T DK15704857T DK3099709T3 DK 3099709 T3 DK3099709 T3 DK 3099709T3 DK 15704857 T DK15704857 T DK 15704857T DK 3099709 T3 DK3099709 T3 DK 3099709T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- manufacture
- methods
- stable antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14153480 | 2014-01-31 | ||
| PCT/NL2015/050054 WO2015115892A1 (en) | 2014-01-31 | 2015-01-30 | Means and methods for producing stable antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3099709T3 true DK3099709T3 (da) | 2020-02-03 |
Family
ID=50031190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15704857.0T DK3099709T3 (da) | 2014-01-31 | 2015-01-30 | Midler og fremgangsmåder til fremstilling af stabile antistoffer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10611829B2 (da) |
| EP (1) | EP3099709B1 (da) |
| JP (1) | JP6747975B2 (da) |
| AU (1) | AU2015211480B2 (da) |
| CA (1) | CA2938193C (da) |
| DK (1) | DK3099709T3 (da) |
| WO (1) | WO2015115892A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014370516B9 (en) * | 2013-12-24 | 2021-07-29 | Kling Biotherapeutics B.V. | Ex vivo antibody production |
| KR102037183B1 (ko) * | 2018-02-09 | 2019-10-28 | 엠랩 주식회사 | 스트리밍 미디어에 코멘트를 맵핑하는 시스템 및 방법 |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997764A (en) | 1987-04-23 | 1991-03-05 | New York University | Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors |
| WO1989008146A1 (en) | 1988-02-26 | 1989-09-08 | Worcester Foundation For Experimental Biology | Inhibition of htlv-iii by exogenous oligonucleotides |
| US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| WO1994007367A1 (en) | 1992-09-29 | 1994-04-14 | Apollon, Inc. | Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids |
| FI951600A7 (fi) | 1992-10-05 | 1995-05-10 | Hybridon Inc | Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine |
| WO1994017086A1 (en) | 1993-01-25 | 1994-08-04 | Apollon, Inc. | Gene regulation by targeting putative intramolecular triple helix |
| US5550019A (en) | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
| US5866755A (en) | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
| EP0716570A4 (en) | 1993-09-03 | 1997-12-17 | Systemix Inc | Genetically Modified Human Hematopoietic Stem Cells and Their Offspring |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US6001558A (en) | 1997-06-25 | 1999-12-14 | Ortho Clinical Diagnostics, Inc. | Amplification and detection of HIV-1 and/or HIV 2 |
| WO2001018185A1 (en) | 1999-09-08 | 2001-03-15 | Genetrol Biotherapeutics, Inc. | High level cytokine production with enhanced cell viability |
| EP1083230A1 (en) | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Viral replicons and viruses dependent on inducing agents |
| US7122180B2 (en) | 2000-10-23 | 2006-10-17 | Children's Medical Center Corporation | DNA vectors containing mutated HIV proviruses |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| JP2003012698A (ja) * | 2001-06-26 | 2003-01-15 | Toyota Central Res & Dev Lab Inc | モノクローナル抗体 |
| ATE515189T1 (de) | 2001-12-10 | 2011-07-15 | California Inst Of Techn | Verfahren zur herstellung von antigenspezifischen lymphozyten |
| US20050009180A1 (en) | 2001-12-10 | 2005-01-13 | Lili Yang | Method for the generation of antigen-specific lymphocytes |
| ES2384960T3 (es) | 2001-12-18 | 2012-07-16 | Cancer Research Technology Limited | Procedimiento para la generación de líneas celulares proliferativas y que se diferencian |
| WO2003068819A1 (en) | 2001-12-22 | 2003-08-21 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| WO2003079757A2 (en) | 2002-03-20 | 2003-10-02 | Massachusetts Institute Of Technology | Hiv therapeutic |
| GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
| MXPA05009556A (es) | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
| AU2004287879C1 (en) | 2003-11-04 | 2011-05-26 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| EP1692276B1 (en) | 2003-11-19 | 2010-07-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of inducing memory b cell development and terminal differentiation |
| GB0327384D0 (en) | 2003-11-25 | 2003-12-31 | Queen Mary & Westfield College | Gene therapy |
| US20050238626A1 (en) | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| WO2005123923A2 (en) | 2004-06-17 | 2005-12-29 | Wolfgang Hillen | Inducer specific tetracycline repressor proteins and methods of use thereof |
| EP1627563A1 (en) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for producing a stabilized cell of interest |
| EP1647595A1 (en) | 2004-10-15 | 2006-04-19 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Nucleic acids against viruses, in particular HIV |
| US7393923B2 (en) | 2004-11-08 | 2008-07-01 | The Regents Of The University Of California | Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same |
| EP1860120B1 (en) | 2005-02-08 | 2018-01-24 | The Chemo-Sero-Therapeutic Research Institute | Method for improving antibody |
| AU2006247067B2 (en) | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
| US20090217403A1 (en) | 2005-06-06 | 2009-08-27 | Hergen Spits | Means and methods for generating a t cell against an antigen of interest |
| CA2630348C (en) | 2005-11-17 | 2016-01-12 | Stichting Voor De Technische Wetenschappen | Inducible expression systems |
| NZ600075A (en) | 2005-12-09 | 2013-12-20 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US9683226B2 (en) | 2009-04-03 | 2017-06-20 | Medical Research Council | Mutants of activation-induced cytidine deaminase (AID) and methods of use |
| WO2011008093A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| CN102666583B (zh) | 2009-07-15 | 2015-11-25 | Aimm医疗股份公司 | 革兰氏阳性细菌特异性结合化合物 |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011043643A1 (en) | 2009-10-06 | 2011-04-14 | Medimmune Ltd | Rsv-specific binding molecule |
| WO2012072814A1 (en) * | 2010-12-02 | 2012-06-07 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| WO2013081463A2 (en) | 2011-12-02 | 2013-06-06 | Aimm Therapeutics B.V. | Influenza a virus specific antibodies |
| JP2015506687A (ja) * | 2012-01-19 | 2015-03-05 | セラピューティック プロテインズ インターナショナル， エルエルシー | 抗−ｃｄ２０抗体リツキシマブの安定化 |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
-
2015
- 2015-01-30 DK DK15704857.0T patent/DK3099709T3/da active
- 2015-01-30 CA CA2938193A patent/CA2938193C/en active Active
- 2015-01-30 EP EP15704857.0A patent/EP3099709B1/en active Active
- 2015-01-30 JP JP2016549244A patent/JP6747975B2/ja active Active
- 2015-01-30 US US15/113,563 patent/US10611829B2/en active Active
- 2015-01-30 WO PCT/NL2015/050054 patent/WO2015115892A1/en not_active Ceased
- 2015-01-30 AU AU2015211480A patent/AU2015211480B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6747975B2 (ja) | 2020-08-26 |
| JP2017504345A (ja) | 2017-02-09 |
| US20170008952A1 (en) | 2017-01-12 |
| AU2015211480A1 (en) | 2016-08-11 |
| NZ723331A (en) | 2021-08-27 |
| AU2015211480B2 (en) | 2020-05-14 |
| CA2938193A1 (en) | 2015-09-06 |
| CA2938193C (en) | 2023-05-02 |
| WO2015115892A1 (en) | 2015-08-06 |
| EP3099709B1 (en) | 2019-12-25 |
| EP3099709A1 (en) | 2016-12-07 |
| BR112016017597A2 (pt) | 2017-08-08 |
| US10611829B2 (en) | 2020-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3185854T3 (da) | Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse | |
| DK3148579T3 (da) | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3827845T3 (da) | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3250610T3 (da) | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3350201T3 (da) | Manipulerede fytaser og fremgangsmåder til anvendelse af samme | |
| DK3365684T3 (da) | Fremgangsmåde til berigelse af cellefrie nukleosomer | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3483593T3 (da) | Luminescent-oxygen-channeling-immunoassay ved anvendelse af tre antistoffer og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf | |
| ZA201701674B (en) | Novel anti-mfi2 antibodies and methods of use |